Looking at all of its recent acquisitions, you might think Endo Pharmaceutical's (NMS:ENDP) business model echoes another firm's. One like Johnson & Johnson's (NYSE:JNJ - News). That makes sense. Endo ...

We are maintaining our Neutral stance on Endo Pharmaceuticals (NasdaqGS:ENDP - News) with a target price of $34.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and ...

Tennessee's Attorney General has filed a lawsuit against drug company Endo Pharmaceuticals for its contribution to the opioid epidemic. The suit alleges that Endo made unlawful and false claims about ...

DUBLIN and MALVERN, Pa., June 13, 2025 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (NDOI) ("Endo") today announced that their respective shareholders have provided the necessary ...

MALVERN, Pa., June 17, 2025 /PRNewswire/ -- Endo, Inc. (NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily ...

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune ...

December 12, 2011 — Endo Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has approved a new crush-resistant formulation of Opana ER. The product will continue to go by ...

At our Pharma & Health Insider Summit in the Poconos, leaders from Sanofi, Pfizer, Takeda, Endo Pharmaceuticals, and Organon shared insights on streamlining the patient journey through AI-powered ...

Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines.